Long-time FDA leader El­lis Unger ex­its as ex­o­dus of high-rank­ing of­fi­cials con­tin­ues

Af­ter al­most 25 years at the FDA, in­clud­ing al­most a decade as a high-pro­file di­rec­tor, El­lis Unger has de­cid­ed to re­tire.

Unger, a car­di­ol­o­gist, has been at the cen­ter of sev­er­al key and con­tentious FDA drug de­ci­sions in re­cent years, con­sis­tent­ly fight­ing against quick ap­provals for drugs with un­known or lim­it­ed ben­e­fits. He’s served as both the FDA’s di­rec­tor of the Of­fice of Drug Eval­u­a­tion-I, be­gin­ning in 2012, and more re­cent­ly tran­si­tioned to di­rec­tor of the Of­fice of Car­di­ol­o­gy, Hema­tol­ogy, En­docrinol­o­gy, and Nephrol­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER